Loading clinical trials...
Loading clinical trials...
OSMITTER 316-13-206A Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period
Conditions
Interventions
Placebo
Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Locations
1
United States
Walnut Creek, California, United States
Start Date
March 21, 2014
Primary Completion Date
April 18, 2014
Completion Date
April 18, 2014
Last Updated
October 26, 2021
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions